Open access

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
James Spicer, Åslaug Helland, Enric Carcereny, Edurne Arriola, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Jonathan Thompson, James Strauss, Ana Laura Ortega Granados, Enriqueta Felip, Emmett Schmidt, Michael Chisamore, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, James Lorens, Matthew Krebs

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A221; DOI: 10.1136/jitc-2020-SITC2020.0362
364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC
Mark Awad, David Spigel, Edward Garon, Saiama Waqar, Aaron Lisberg, Melissa Moles, Jennifer Tepper, April Lamb, Amy Wanamaker, Zakaria Khondker, John Srouji, Jesse Dong, Asaf Poran, Kristen Balogh, Meghan Bushway, Mark DeMario, Lakshmi Srinivasan, Richard Gaynor, Ramaswamy Govindan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A222; DOI: 10.1136/jitc-2020-SITC2020.0364
363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
Byoung Chul Cho, Ki Hyeong Lee, Ji-Youn Han, Byoung Yong Shim, Hye Ryun Kim, Kyoung-Ho Pyo, Jae-Hwan Kim, Chung-Feng Xin, Jin Kyung Lee, Jiyeon Ryu, Bitna Oh, Sunjin Hwang, Ki Baik Hahm, Seong-Jin Kim

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A222; DOI: 10.1136/jitc-2020-SITC2020.0363
365 Tumor treating fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR Study
Ticiana Leal, Raphael Bueno, Libor Havel, Jeffrey Ward

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A223; DOI: 10.1136/jitc-2020-SITC2020.0365
367 A phase 1/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with atezolizumab in patients with advanced solid tumors
Jason Luke, Filip Janku, Anthony Olszanski, Kevin Leach, Radhakrishnan Iyer, Atif Abbas

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A224; DOI: 10.1136/jitc-2020-SITC2020.0367
371 The association of the gut microbiota and clinical response to immune checkpoint inhibitors in patients with advanced cancer
Cheng-Hsun Chiu, Chih-Yu Tsai, Yu-Fen Lin, John Chang, Chiao-En Wu, Yuan-Ming Yeh, Yung–Chi Shen, Ming-Mo Hou, Jia-Juan Hsieh, John Chang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A226; DOI: 10.1136/jitc-2020-SITC2020.0371
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
Nicole Toney, Yo-Ting Tsai, Claire Rumfield, Samuel Pellom, Caroline Jochems, Julius Strauss, James Gulley, Jeffrey Schlom, Renee Donahue

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A228-A229; DOI: 10.1136/jitc-2020-SITC2020.0375
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Susanna Ulahannan, Haider Mahdi, Manmeet Ahluwalia, Manish Patel, Afshin Dowlati, Andrea Bullock, Patrick Wen, Shubham Pant, Mary Mulcahy, Robert Guttendorf, Lou Vaickus, Suming Wang, Marsha Crochiere, Melanie Vincent, Michael Cieslewicz, Jing Watnick

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A228; DOI: 10.1136/jitc-2020-SITC2020.0374
39 Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas
Katie Blise, Shamilene Sivagnanam, Lisa Coussens, Jeremy Goecks

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A23-A24; DOI: 10.1136/jitc-2020-SITC2020.0039
38 Clinical validation of an image analysis assay for determining programmed death-ligand 1 (22C3) in non-small cell lung cancer
Roberto Gianani, Will Paces, Elliott Ergon, Kristin Shotts, Vitria Adisetiyo, Charles Caldwell

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A23; DOI: 10.1136/jitc-2020-SITC2020.0038

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages